Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 29 clinical trials
featured
A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected with Chronic HCV who have Advanced Liver Disease or are Post-Liver Transplant

A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected with Chronic HCV who

  • 444 views
  • 08 Nov, 2020
  • 1 location
Effect of Sofosbuvir-daclatasuvir on Angiogenesis

The study aimed at study of the Effect of Daclatasvir Plus Sofosbuvir on Angiogenesis in Egyptian Patients With Chronic HCV Infection

  • 0 views
  • 22 Jan, 2021
  • 1 location
Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients

efficacy and safety of Sofosbuvir containing regimens in treatment of COVID-19 Egyptian patients,

  • 0 views
  • 27 Jan, 2021
  • 2 locations
Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir

A single-arm, single-center, open label Phase 1 study of a 12-week course of Sofosbuvir (SOF)/Velpatasvir (VEL) in 10 HCV-infected pregnant women 1 that will evaluate the plasma pharmacokinetic

chronic hepatitis
hepatitis b
velpatasvir
sofosbuvir
  • 0 views
  • 26 Jan, 2021
  • 1 location
Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders

This study aims to assess the role of ribavirin as an adjuvant to sofosbuvir/velpatasvir/voxilaprevir combination in retreatment of chronic hepatitis C with previous treatment failure.

  • 0 views
  • 28 Jan, 2021
  • 1 location
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-na ve Patients With Chronic Hepatitis C Genotype 1

Multicenter, open-label, phase II safety and efficacy study of all-oral combination of narlaprevir/ritonavir and sofosbuvir in Treatment-nave Patients with Chronic Hepatitis C Genotype 1.

  • 0 views
  • 23 Jan, 2021
  • 5 locations
Re-treatment of HCV Following DAA Failure

HCV infection is treated with oral drugs, termed as 'direct-acting anti-viral agents' (DAAs). In India, four DAAs are available (sofosbuvir [SOF], daclatasvir [DCV], ledipasvir [LDV] and

daclatasvir
velpatasvir
ribavirin
cirrhosis
hcv genotype
  • 19 views
  • 11 Apr, 2021
  • 2 locations
Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera

Hepatitis C virus (HCV) infection is associated with significant morbidity and mortality owing to progression of a high percentage (85%) of HCV infected patients to chronic hepatitis, which might lead to the development of liver cirrhosis or hepato cellular carcinoma.. Egypt has possibly the highest HCV prevalence in the world, …

  • 0 views
  • 24 Mar, 2021
  • 1 location
The Kentucky Viral Hepatitis Treatment Study

The overarching goal of the Kentucky Viral Hepatitis Treatment Project (KeY Treat) is to increase hepatitis C virus (HCV) treatment access and delivery in a rural Appalachian community, which is in the midst of the opioid/hepatitis C (HCV) syndemic. KeY Treat is a clinical research study seeking to determine whether …

sofosbuvir/velpatasvir
velpatasvir
viral hepatitis
epclusa
opioid
  • 7 views
  • 23 Jan, 2021
  • 1 location
Sofosbuvir in Treatment of COVID 19

Sofosbuvir containing treatment in treatment of COVID 19 Egyptian patients

  • 0 views
  • 26 Jan, 2021
  • 1 location